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Children carrying a germline mutation in
one allele of RB1 are highly predisposed
to retinoblastoma, a tumor of the retina.
Based on this hereditary predisposition,
Knudson proposed the “two-hit” hypothe-
sis, which was subsequently validated by
the demonstration that the loss of the
second allele of RB1 is a rate-limiting
step for retinoblastoma development
(Knudson, 2001). However, the precise
function of the retinoblastoma protein,
pRB, in normal retinal homeostasis is still
unknown. In addition, the cell of origin of
retinoblastoma has not been established.
That is, until now. In this issue, Bremner
and colleagues describe the generation
of the first inheritable mouse model for
retinoblastoma (Chen et al., 2004).
Interestingly, they show that loss of pRb
and the pRb related protein, p107, specif-
ically impairs cell cycle exit of retinal pre-
cursors, but does not prevent terminal
differentiation. Based on a careful analy-
sis of retinal development in the mouse
model, they propose that tumors arise
from cells that have escaped terminal dif-
ferentiation rather than cell death, and
point to an amacrine precursor as the
“cell-of-origin” for retinoblastoma.
Unlike humans, Rb heterozygous
mice do not develop retinoblastoma, but
are instead highly predisposed to pitu-
itary and thyroid tumors (for review, see
Classon and Harlow, 2002). Due to the
embryonic lethality of Rb null mice, it has
been challenging to establish the func-
tion of pRb in the retina at later stages of
development. The first clues came from
an analysis of chimeric Rb+/−mice, which
demonstrated a poor contribution of Rb−/−
cells to the adult retina. The lack of Rb
null cells in the adult retina was ascribed
to apoptosis (Maandag et al., 1994),
suggesting that Rb−/− cells must escape
apoptosis in the development of
retinoblastoma. Consistent with this,
expression of E7, which inactivates pRB
family members, induces cell death in
the retina, whereas its expression in 
p53−/− photoreceptors induces tumor for-
mation (Classon and Harlow, 2002).
Moreover, the simultaneous inactivation
of both the pRb and p53 pathways by
expression of SV40 T antigen in the
murine retina also results in tumor for-
mation (Classon and Harlow, 2002).
However, the absence of p53 mutations
in human retinoblastomas raises the
concern of whether these mouse models
mimic the development of human
retinoblastomas.
The demonstration that Rb+/−; p107−/−
compound mice develop retinal dyspla-
sia was a key step toward the generation
of an inheritable mouse model for human
retinoblastoma (Lee et al., 1996). This
finding was further supported by the
observation that chimeric mice derived
from Rb−/−; p107−/− embryonic stem cells
suffer from retinoblastoma originating
from the inner nuclear layer (INL) of the
retina with amacrine cell characteristics
(Robanus-Maandag et al., 1998).
However, the fact that some but not all
chimeric retinas form retinoblastomas
and that the majority of Rb−/−; p107−/−
retinoblasts undergo apoptosis suggests
that in addition to loss of pRb and p107,
other mutations could be required to
counteract cell death and allow tumor
development.
The inheritable mouse model for
retinoblastoma described by Bremner
and colleagues is based on the retinal-
specific ablation of pRb in a p107−/−
genetic background. Interestingly, the
careful analysis of the mice has led the
P R E V I E W S
Naturally death-resistant precursor cells revealed as the origin of
retinoblastoma
The molecular mechanisms and the cell-of-origin leading to retinoblastoma are not well defined. In this issue of Cancer
Cell, Bremner and colleagues describe the first inheritable model of retinoblastoma, revealing that loss of the pocket pro-
teins pRb and p107 deregulates cell cycle exit in retinal precursors. The authors show that a subset of these precursors
contain an inherent resistance to apoptosis, and that while most terminally differentiate, some are likely to acquire addi-
tional mutations, leading to tumor formation.Thus, this work defines the cell-of-origin of retinoblastoma and suggests that
mutations giving increased proliferative capacity are required for retinoblastoma development.
Figure 1. Model for retinoblastoma
development
Retinal development involves 7 different cell
types and is characterized by expansion of
progenitor cells, specification of precursors,
and terminal differentiation. Mice lacking
pRb and p107 (−/−) carry out all of these reti-
nal developmental processes in a manner
similar to wild-type mice (+/+, dashed lines).
However, pRb/p107 deficiency results in
ectopic division of all retinal precursors (−/−,
in red). One group of precursors subsequent-
ly undergoes apoptosis (death-prone), while
another group is resistant (naturally death-
resistant). Retinoblastoma arises from these
naturally death-resistant precursors after
they have acquired additional mutations
(M). These as yet to be identified mutations
presumably facilitate continued prolifera-
tion, ultimately leading to retinoblastoma.
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authors to challenge the view that tumors
arise from acquired resistance to
apoptosis. Critically, the work provides a
very comprehensive analysis of the cell-
specific effects of pRb loss during retinal
development. Specifically, they demon-
strate that loss of pRb or combined loss
of pRb/p107 does not affect retinal prog-
enitor expansion, precursor specification,
or terminal differentiation. In contrast,
loss of pRb and p107 results in ectopic
division of all precursors at a time when
proliferation normally ceases (Figure 1).
This supports a model in which
retinoblastoma arises from the ectopical-
ly dividing precursors rather than progen-
itors. Surprisingly, however, the large
majority of double knockout precursors
divide ectopically only for a finite period of
time and ultimately undergo terminal dif-
ferentiation.This result demonstrates that
pRb and p107 loss is not sufficient to pro-
vide infinite proliferating capacity to pre-
cursors, and strongly suggests that
additional mutations are required for the
subsequent development of retinoblas-
tomas. Consistent with the cell death
reported for the chimeric mice, massive
apoptosis in the Rb−/−; p107−/− retina was
also observed. Interestingly, the loss of
pRb and p107 results in apoptosis in four
precursor subtypes (ganglion, bipolar,
rod, and cone), whereas the remaining
INL precursors (horizontal, amacrine,
and Müller cells) undergo ectopic cell
proliferation without displaying signs of
apoptosis. The accelerated proliferation
induced by loss of pRb and p107 com-
bined with the natural death resistance of
the INL precursors suggests that these
cells are the prime candidates for the cell-
of-origin in retinoblastomas. Indeed,
emerging and mature tumors express
markers characteristic for amacrine cells
and, to a lesser extent, Müller cells.
These results are consistent with other
reports (Robanus-Maandag et al., 1998;
Chen et al., 2004; MacPherson et al.,
2004), and the authors therefore propose
a model in which intrinsically death-
resistant INL precursors with limited pro-
liferative capacity require additional
mutation(s) to overcome differentiation-
associated growth arrest. Importantly,
this implies that the most critical barrier to
retinal transformation is terminal differen-
tiation rather than apoptosis, as previous-
ly suspected.
Whether INL precursors are also the
origin of human retinoblastoma remains
unclear. In fact, both outer (ONL) and
inner nuclear layer (INL) precursor mark-
ers have been detected in human retinal
tumors. However, Gallie et al. demon-
strated that early stage human
retinoblastomas in fact exhibit a nuclear
morphology typical of INL (Gallie et al.,
1999), suggesting that the ONL charac-
teristics observed in late stage tumors
may be due to transdifferentiation
events.
The work presented in this issue of
Cancer Cell and by the Jacks group in
Genes & Development firmly establishes
that while pRb loss is not sufficient to
induce retinoblastomas in mice, the com-
pound Rb−/−; p107−/− or Rb−/−; p130−/−
mutant mice develop retinoblastoma with
high incidence (Robanus-Maandag et
al., 1998; Chen et al., 2004; MacPherson
et al., 2004). This points to overlapping
functions between the pocket proteins
during retinal development and suggests
that p107 and p130 can compensate for
loss of pRB in the control of retinal
homeostasis. Since the pRB family
members display overlapping functions,
it is tempting to speculate that ablation of
all three pRB family proteins in murine
retina would further enhance the tumor
formation phenotype.
An important question is whether
the conclusions derived from the mouse
models are relevant for human
retinoblastomas. Significantly, whereas
germline mutation of one RB1 allele in
humans leads to the development of
retinoblastoma with 100% penetrance,
the tumor incidence drops to 60% in the
mouse model described by Chen and
colleagues (Chen et al., 2004). Since
previous data have shown that the phe-
notypes arising in p107 or p130 mutant
mice are strongly dependent on their
genetic background (Classon and
Harlow, 2002), it is possible that genetic
modifiers partially compensate for com-
bined loss of p107 and pRB in this
mouse model, thus suggesting that the
penetrance might be higher in other
mice strains. Moreover, the safeguard
mechanisms operating in human and
mouse may be different, because muta-
tions in the p107 gene have not been
found in human retinoblastoma.
However, it is possible that pRB-related
proteins are also involved in retinal
tumor development in humans, since
p130 expression has been reported to
be strongly downregulated in a subset
of retinoblastomas (Bellan et al., 2002).
Furthermore, additional genetic alter-
ations in   addition to RB1 mutations
have been described in human
retinoblastomas. Specifically, the vast
majority of retinoblastomas examined
exhibit either a discrete genomic ampli-
fication of chromosome 6p (isochromo-
some of 6p) or extra copies of
chromosome 1q (Chen et al., 2001).
Identification of the crucial genes
involved in these cytogenetic alterations
could provide important information to
help further understand the genesis of
human retinoblastoma. A candidate
oncogene, the human kinesin gene
RBKIN/KIF13A, has been found located
within the amplified region of chromo-
some 6p, and consistently, it is highly
expressed in retinoblastomas and
required for growth of retinoblastoma
cell lines.
As in human retinoblastoma, the
mouse model described by Bremner and
colleagues shows that genetic alter-
ations, in addition to pRb inactivation,
are required for the development of
retinoblastomas. It will be extremely
interesting to identify these genes and to
test their relevance in human cancer.
Therefore, it is likely this inheritable
mouse model of retinoblastoma will be
an invaluable tool in our efforts to under-
stand not only the genesis of retinoblas-
toma, but cancer in general. Already, it
has provided the provocative possibility
that the cell-of-origin of retinoblastoma in
humans might have to escape the barrier
of terminal differentiation, as opposed to
apoptosis as previously thought.
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When considering the p53 gene family,
one is struck by their conspicuous simi-
larities as well as their intriguing differ-
ences. Structurally, the p53 family
members’ kinship is obvious, as they
share a common domain topology and
bear significant sequence homology
within their transactivation, DNA binding,
and tetramerization domains (reviewed in
Melino et al., 2002). At this point, howev-
er, far more is understood about p53 and
its function as a pivotal node in the DNA
damage checkpoint. Upon genotoxic
insult, p53 becomes modified, stabilized,
and thereby activated to regulate tran-
scription of its downstream target genes
important in many cellular functions,
including cell cycle arrest and apoptosis.
While p53’s central role in apoptosis and
tumor suppression is proven, the extent
to which the other members of the p53
family can support or recapitulate its
functions is unclear. Nevertheless, p73
can activate at least a subset of p53 tar-
get genes independently of p53 and also
can mediate p53-independent apoptosis
in response to a number of chemothera-
peutic agents (Irwin et al., 2003).
Interestingly, however, p63 and p73 are
required for p53-dependent apoptosis as
well as activation of some proapoptotic
p53 target genes in mouse embryo
fibroblasts expressing E1a in response to
cytotoxic agents (Flores et al., 2002).
Understanding the mechanisms by which
the p53 family members individually and
together regulate transcription continues
to be an important challenge for revealing
their respective roles in tumor
suppression.
A recent elegant paper from
Montovani et al. links p73 with the Pin1
peptidyl-prolyl-isomerase in apoptosis,
and as such may begin to provide a
mechanism for coregulation of the p53
family (Montovani et al., 2004). Pin1 medi-
ates cis/trans isomerization of proteins at
serine-proline or threonine-proline (SP or
TP) motifs. The ensuing conformational
change produces a variety of functional
outcomes in many proteins central to
tumorigenesis, including cyclin D1, β
catenin, NF-κB, and even p53 itself.
Substrate recognition by Pin1 requires
phosphorylation of SP or TP motifs by
multiple families of proline-directed kinas-
es, including cyclin-dependent kinases
(CDKs) and mitogen-activated protein
kinases (MAPKs) (reviewed in Lu, 2003).
Montovani et al. demonstrate that
Pin1 strongly enhances p73-dependent
apoptosis in p53 null cell lines, an obser-
vation that correlates with the ability of
Pin1 to augment p73’s ability to induce
proapoptotic target genes, including
Bax, Pig3, and p53AIP1. The Pin1-p73
interaction is phosphorylation-depen-
dent and seems to be mediated by three
key phosphorylation sites within the
poly-proline region of p73 that exist only
in the α and β isoforms of this protein.
Mutation of these 3 residues abrogates
Pin1 binding as well as transcriptional
regulatory activity of p73. Furthermore,
the authors show by a partial proteolysis
assay that Pin1 can directly induce con-
formational change(s) in p73 in vitro,
indicating that the Pin1-p73 interaction is
direct and that p73 is a bona fide sub-
strate for Pin1 isomerization. Binding of
Pin1 often enhances substrate half-life,
and indeed, siRNA-mediated knockdown
of Pin1 destabilizes p73 protein both in
the presence and absence of DNA
damage.
The signaling pathway converging
on p73, activated by two chemothera-
peutic agents cisplatinum (CDDP) and
adriamycin (ADR), relies principally on
the c-Abl tyrosine kinase (White and
Prives, 1999). Direct phosphorylation of
p73 by c-Abl on Y99, among other sites,
can stabilize and activate p73 protein.
Connecting this pathway with Pin1 is
the finding that c-Abl activates proline-
directed p38 MAPK to phosphorylate
TP sites within p73 (Sanchez-Prieto et
al., 2002).Thus, the c-Abl pathway likely
creates Pin1 recognition motifs on p73
through MAPK. Indeed, Montovani et al.
show that CDDP and ADR as well as
overexpression of c-Abl or p38-MAPK
stimulate Pin1-p73 association. This is
dependent on c-Abl, as p73 mutated at
Y99 is not active in these assays, and
siRNA depletion of c-Abl inhibits the
p73-Pin1 association. Conversely, c-Abl
cannot stabilize or activate p73 in the
context of Pin1 knockdown by siRNA.
Taken together, these observations
strongly implicate a strict functional
interdependence between c-Abl and
Pin1 in activating p73 after genotoxicity.
In addition to tyrosine phosphoryla-
tion, c-Abl is also required for p300-
dependent acetylation of p73, and this
modification enhances activation of pro-
apoptotic p73 target promoters (Costanzo
et al., 2002). Indeed, Montovani et al.
found that DNA damage-dependent p73
acetylation is defective in Pin1 null cells,
and coexpression of Pin1 enhances both
the p300-p73 interaction as well as the
The linchpin? Pin1 meets p73
A recent paper shows that the peptidyl-prolyl isomerase Pin1 conformationally alters p73, promoting its acetylation by
p300 in a c-Abl dependent manner. Given previous findings with p53, Pin1 may represent a common mediator linking pro-
apoptotic cooperative activity of the p53 family members.
